Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Kordower, Jeffrey
PropertyValue
overview Other Appointments: Director, Section of Neurobiology Overview: Kordower is an international authority in the area of movement disorders with special expertise in pathophysiology and experimental therapeutic strategies in Parkinson’s disease, Alzheimer’s disease and Huntington’s disease — especially using nonhuman primate models. He has published landmark papers in the area of cell replacement strategies, including the first demonstration that fetal dopaminergic grafts can survive, innervate and form synapses in patients with Parkinson’s disease that was published in the New England Journal of Medicine. His recent demonstration that long-term grafts in such patients can form Lewy bodies was recently published in Nature Medicine. Kordower has published seminal studies including the lead article in Science demonstrating that gene delivery of the trophic factors GDNF and neurturin can prevent the emergence of motor symptoms and nigrostriatal degeneration in a monkey model of PD. He also was the first to demonstrate that gene delivery of trophic factors can obviate neurodegenerative processes in nonhuman primate models of Huntington’s disease and Alzheimer’s disease, with these studies being published in Nature and The Journal of Comparative Neurology, respectively. He has published numerous papers investigating the role of misfolded proteins in PD pathogenesis. These include papers in human and experimental PD on the role of alpha synuclein misfolding on Nurr1 and dopamine expression, lysosome and proteasome dysfunction, and axonal transport defects. He is a co-author on the landmark Nature paper lead by the Studer group demonstrating the structural and functional efficacy of dopaminergic human stem cells in rodent and nonhuman primate models of PD. In addition, he is collaborating with Trojanowski and Lee and recently demonstrated the ability of preformed fibrils to be transported in nonhuman primates and cause degeneration in nonhuman primates, a study that serves as the foundation of the current application. Kordower has published over 350 papers, has lectured all over the world, has been on over 20 editorial boards, and is on the SAB’s of many biotech companies and scientific organizations. He is a past councilor and past president of the American Society for Neural Transplantation, past chair for the Committee for the Use of Animals for SFN, and is a founding SAB member for the Michael J. Fox Foundation and is a past member of their Executive SAB. My Scopus ID is 7005337450. My NIH COMMONS name is JKORDOWER. Education PhD, Queens College, City University of New York MA, Queens College, City University of New York BA, Queens College, City University of New York
One or more keywords matched the following items that are connected to Kordower, Jeffrey
Item TypeName
Concept Neurturin
Academic Article Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
Academic Article Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.
Academic Article Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Academic Article AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned?
Academic Article Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.
Academic Article Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum.
Academic Article Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Academic Article AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
Academic Article Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point.
Academic Article Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease.
Academic Article Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
Academic Article Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
Academic Article Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
Academic Article Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies.
Academic Article Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease.
Academic Article GDNF signaling in subjects with minimal motor deficits and Parkinson's disease.
Academic Article Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery.
Search Criteria
  • Neurturin